Resolute Zotarolimus-Eluting Stents in CTOs Evaluated in 5-Year Pooled Analysis

March 19, 2021—Findings from a pooled analysis of 5-year outcomes of the Resolute zotarolimus-eluting stent (R-ZES, Medtronic) in treating coronary total occlusions (CTOs) were published by Henning Kelbæk, MD, et al in EuroIntervention (2021;16:1326-1332).

As summarized in EuroIntervention, the data of patients treated with R-ZES in four trials (RESOLUTE All Comers, RESOLUTE International, RESOLUTE China RCT, and RESOLUTE China Registry) were pooled and divided into three groups: patients with CTO, patients with total occlusions that had occurred recently (rec-TO), and patients without total occlusions (non-TO). Clinical outcomes at 5 years were analyzed.

The trials included 5,487 patients treated with R-ZES. Patients had a mean age of 62.8 years, approximately 25% were women, and 30% had diabetes.

Of these patients, 8% had CTOs, 8.5% rec-TOs, and 83.5% non-TOs.

The investigators found that target lesion failure was similar in the three groups at 5 years: 13.2%, 12.5%, and 13.3% in the CTO, rec-TO, and non-TO groups, respectively; P = .96). Stent thrombosis tended to occur more frequently for rec-TO compared to CTO and non-TO patients (2.6% vs 1.2% and 1.3%, respectively; P = .11).

In this large population of patients who had R-ZES implanted, 5-year clinical outcomes were similar whether or not the stents were implanted in total occlusions, concluded the investigators in EuroIntervention.